

Ontario Public Drug Programs

Drug Submission Status
Updated: August 17, 2012

Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp-Rizatriptan	Maxalt	rizatriptan benzoate	5mg	tablet	02380455
Jamp Pharma Corporation	Jamp-Rizatriptan	Maxalt	rizatriptan benzoate	10mg	tablet	02380463
Auro Pharma Inc.	Auro-Pioglitazone	Actos	pioglitazone hydrochloride	15mg	uncoated tablet	02384906
Auro Pharma Inc.	Auro-Pioglitazone	Actos	pioglitazone hydrochloride	30mg	uncoated tablet	02384914

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Auro Pharma Inc.	Auro-Pioglitazone	Actos	pioglitazone hydrochloride	45mg	uncoated tablet	02384922
Genmed, A Division of Pfizer Canada Inc.	GD-Terbinafine	Lamisil	terbinafine hydrochloride	250mg	uncoated tablet	02352818
Genmed, A Division of Pfizer Canada Inc.	GD-Gabapentin	Neurontin	gabapentin	600mg	FC tablet	02285843
Genmed, A Division of Pfizer Canada Inc.	GD-Gabapentin	Neurontin	gabapentin	800mg	FC tablet	02285851
Marcan Pharmaceuticals Inc.	Mar-Olanzapine ODT	Zyprexa Zydis	olanzapine	20mg	OD tablet	02389126
Mint Pharmaceuticals Inc.	Mint-Metformin	Glucophage	metformin HCl	850mg	tablet	02388774
Sandoz Canada Inc.	Sandoz Ciprofloxacin	Ciloxan	ciprofloxacin HCl	0.3%	ophthalmic solution	02387131